Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy

Clara De Simone, Federico Pirro, Ketty Peris, Giacomo Caldarola, M. Galluzzo, N. Bernardini, G. Moretta, S. Pallotta, E. Botti, E. Campione, C. Potenza, L. Bianchi

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Background: Information is limited from real-life studies evaluating the efficacy and safety of brodalumab.Research design and methods: In this real-life study, we retrospectively examined a database of 90 patients with moderate-to-severe psoriasis treated with brodalumab (210 mg, s.c.) and followed for 1 year. Disease severity and treatment response were assessed by the Psoriasis Area and Severity Index (PASI) at baseline and after 4, 12, 24, 36, and 48 weeks. Predictors of a PASI response were evaluated by logistic regression.Results: After 48 weeks, 92.2% of patients (mean age 50.2 ± 15 years) treated with brodalumab achieved a PASI score of <3. PASI score decreased from 17.4 ± 10.3 at baseline to 1.7 ± 3.9 and 1.4 ± 3.7 at 12 and 24 weeks, and PASI 75, 90, and 100 response was achieved in 87.3%, 81.8%, and 72.7% of patients, respectively, at 48 weeks. Univariate regression revealed that previous exposure to anti-IL17A treatment was associated with poorer PASI response between 36 and 48 weeks. In difficult-to-treat cases previously having failed with other biologics, brodalumab significantly improved outcome, leading to complete remission.Conclusion: Brodalumab was observed to be effective and safe in patients with moderate-to-severe chronic psoriasis in a real-world setting.
Lingua originaleEnglish
pagine (da-a)1299-1310
Numero di pagine12
RivistaExpert Opinion on Biological Therapy
Volume21
DOI
Stato di pubblicazionePubblicato - 2021

Keywords

  • Anti-il17a
  • brodalumab
  • erythroderma
  • real-life
  • plaque psoriasis
  • pustular
  • PASIpsoriasis

Fingerprint

Entra nei temi di ricerca di 'Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy'. Insieme formano una fingerprint unica.

Cita questo